公开(公告)号：US20200369658A1

公开(公告)日：2020-11-26

申请号：US16990150

申请日：2020-08-11

Applicant: Mission Therapeutics Limited

Inventor： Alison Jones ,  Mark Ian Kemp ,  Martin Lee Stockley ,  Karl Richard Gibson ,  Gavin Alistair Whitlock ,  Andrew Madin

IPC: C07D417/12 ,  C07D403/12 ,  C07D401/12 ,  C07D413/12 ,  C07D417/14 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D513/04

Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.

公开(公告)号：US11993595B2

公开(公告)日：2024-05-28

申请号：US17901390

申请日：2022-09-01

Applicant: Mission Therapeutics Limited

Inventor： Alison Jones ,  Mark Ian Kemp ,  Martin Lee Stockley ,  Karl Richard Gibson ,  Gavin Alistair Whitlock ,  Andrew Madin

IPC: C07D417/12 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D513/04

CPC classification number: C07D417/12 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D513/04

Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.

公开(公告)号：US11370784B2

公开(公告)日：2022-06-28

申请号：US16336685

申请日：2017-10-04

Applicant: MISSION THERAPEUTICS LIMITED

Inventor： Martin Lee Stockley ,  Mark Ian Kemp ,  Andrew Madin

IPC: C07D413/12 ,  C07D265/30 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04

Abstract: The present invention relates to cyano-substituted-heterocycles of Formula (I) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30), having utility in a variety of therapeutic areas including cancer and conditions involving mitochondrial dysfunction.

公开(公告)号：US11958833B2

公开(公告)日：2024-04-16

申请号：US17402802

申请日：2021-08-16

Applicant: MISSION THERAPEUTICS LIMITED

Inventor： Mark Ian Kemp ,  Martin Lee Stockley ,  Andrew Madin

IPC: C07C201/00 ,  A61K31/4025 ,  A61K31/407 ,  A61K31/4725 ,  A61P3/00 ,  A61P3/10 ,  A61P9/00 ,  A61P19/02 ,  A61P21/00 ,  A61P25/00 ,  A61P25/14 ,  A61P25/16 ,  A61P25/28 ,  A61P35/00 ,  A61P35/04 ,  A61P43/00 ,  C07D207/09 ,  C07D401/12 ,  C07D403/12 ,  C07D403/14 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04

CPC classification number: C07D403/12 ,  A61P25/00 ,  A61P35/04 ,  C07D403/14 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04

Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or Ubiquitin Specific Peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the Invention include compounds having the formula (I): (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R1c, R1d, R1e, R1f, R1g, R2, X, L and A are as defined herein.

公开(公告)号：US11472798B2

公开(公告)日：2022-10-18

申请号：US16990150

申请日：2020-08-11

Applicant: Mission Therapeutics Limited

Inventor： Alison Jones ,  Mark Ian Kemp ,  Martin Lee Stockley ,  Karl Richard Gibson ,  Gavin Alistair Whitlock ,  Andrew Madin

IPC: C07D417/12 ,  C07D403/12 ,  C07D401/12 ,  C07D413/12 ,  C07D417/14 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D513/04

Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.

公开(公告)号：US11130748B2

公开(公告)日：2021-09-28

申请号：US15781615

申请日：2016-12-16

Applicant: MISSION THERAPEUTICS LIMITED

Inventor： Mark Ian Kemp ,  Martin Lee Stockley ,  Andrew Madin

IPC: A61P35/00 ,  A61P35/04 ,  A61P25/16 ,  A61P25/28 ,  A61P25/00 ,  A61P25/14 ,  A61P9/00 ,  A61P43/00 ,  A61P3/00 ,  A61P3/10 ,  C07D487/04 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D403/14 ,  C07D207/09 ,  C07D471/04 ,  C07D401/12 ,  C07D403/12

Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or Ubiquitin Specific Peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (I): (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R1c, R1d, R1e, R1f, R1g, R2, X, L and A are as defined herein.

公开(公告)号：US11091488B2

公开(公告)日：2021-08-17

申请号：US15776149

申请日：2016-11-29

Applicant: MISSION THERAPEUTICS LIMITED

Inventor： Mark Ian Kemp ,  Martin Lee Stockley ,  Andrew Madin

IPC: C07D487/04 ,  A61P25/28 ,  A61P35/00 ,  C07D401/12 ,  C07D403/12 ,  C07D413/12 ,  C07D417/04 ,  C07D417/14 ,  C07D513/04

Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylatin-enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or Ubiquitin Specific Peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (I) (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, m, L and X are as defined herein.

公开(公告)号：US11084821B2

公开(公告)日：2021-08-10

申请号：US16336202

申请日：2017-10-02

Applicant: MISSION THERAPEUTICS LIMITED

Inventor： Martin Lee Stockley ,  Mark Ian Kemp ,  Andrew Madin

IPC: C07D487/04 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12 ,  C07D471/04 ,  C07D498/04 ,  A61K31/407

Abstract: The present invention relates to a class of substituted-cyanopyrrolidines of Formula (I) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30), having utility in a variety of therapeutic areas including cancer and conditions involving mitochondrial dysfunction.

公开(公告)号：US10683269B2

公开(公告)日：2020-06-16

申请号：US16080506

申请日：2017-03-17

Applicant: MISSION THERAPEUTICS LIMITED

Inventor： Karl Richard Gibson ,  Alison Jones ,  Mark Ian Kemp ,  Andrew Madin ,  Martin Lee Stockley ,  Gavin Alistair Whitlock ,  Michael D Woodrow ,  Keith Allan Menear

IPC: C07D209/44 ,  C07D403/10 ,  C07D403/04 ,  C07D401/04 ,  C07D471/04 ,  C07D413/04 ,  C07D401/12 ,  C07D413/12 ,  C07D409/12 ,  A61P35/00 ,  C07D519/00 ,  C07D403/14 ,  C07D487/04 ,  C07D401/06 ,  C07D405/12 ,  C07D401/14 ,  C07D413/14 ,  C07D413/10 ,  C07D403/12 ,  C07D417/12

Abstract: The invention relates to novel compounds of formula I which are inhibitors of deubiquitylating enzymes (DUBs) and/or desumoylating enzymes. In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 7 or ubiquitin specific peptidase 7 (USP7). The invention further relates to methods for the preparation of these compounds and to their use in the treatment of cancer.

公开(公告)号：US20230052191A1

公开(公告)日：2023-02-16

申请号：US17901390

申请日：2022-09-01

Applicant: Mission Therapeutics Limited

Inventor： Alison Jones ,  Mark Ian Kemp ,  Martin Lee Stockley ,  Karl Richard Gibson ,  Gavin Alistair Whitlock ,  Andrew Madin

IPC: C07D417/12 ,  C07D403/12 ,  C07D401/12 ,  C07D413/12 ,  C07D417/14 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D513/04

Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.